Miglitol

Revision as of 18:38, 27 September 2011 by WikiBot (talk | contribs) (Protected "Miglitol": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Miglitol
Error creating thumbnail: File missing
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • AU: B3
  • US: B (No risk in non-human studies)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityDose-dependent
Protein bindingNegligible (<4.0%)
MetabolismNil
Elimination half-life2 hours
ExcretionRenal (95%)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC8H17NO5
Molar mass207.224 g/mol

WikiDoc Resources for Miglitol

Articles

Most recent articles on Miglitol

Most cited articles on Miglitol

Review articles on Miglitol

Articles on Miglitol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Miglitol

Images of Miglitol

Photos of Miglitol

Podcasts & MP3s on Miglitol

Videos on Miglitol

Evidence Based Medicine

Cochrane Collaboration on Miglitol

Bandolier on Miglitol

TRIP on Miglitol

Clinical Trials

Ongoing Trials on Miglitol at Clinical Trials.gov

Trial results on Miglitol

Clinical Trials on Miglitol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Miglitol

NICE Guidance on Miglitol

NHS PRODIGY Guidance

FDA on Miglitol

CDC on Miglitol

Books

Books on Miglitol

News

Miglitol in the news

Be alerted to news on Miglitol

News trends on Miglitol

Commentary

Blogs on Miglitol

Definitions

Definitions of Miglitol

Patient Resources / Community

Patient resources on Miglitol

Discussion groups on Miglitol

Patient Handouts on Miglitol

Directions to Hospitals Treating Miglitol

Risk calculators and risk factors for Miglitol

Healthcare Provider Resources

Symptoms of Miglitol

Causes & Risk Factors for Miglitol

Diagnostic studies for Miglitol

Treatment of Miglitol

Continuing Medical Education (CME)

CME Programs on Miglitol

International

Miglitol en Espanol

Miglitol en Francais

Business

Miglitol in the Marketplace

Patents on Miglitol

Experimental / Informatics

List of terms related to Miglitol

For patient information, click here

Miglitol is an oral anti-diabetic drug that acts by inhibiting the ability of the patient to breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body.

Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. Since miglitol works by preventing digestion of carbohydrates, it lowers the degree of postprandial hyperglycemia. It must be taken at the start of main meals to have maximal effect. Its effect will depend on the amount of non-monosaccharide carbohydrates in a person's diet.

In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.

See also

Template:Oral hypoglycemics Template:SIB


Template:WikiDoc Sources